Results 1 to 10 of about 10,059 (251)

Anidulafungin in the treatment of invasive fungal infections

Therapeutics and Clinical Risk Management, 2008
Kathryn Sabol, Tawanda GumboUniversity of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: More antifungal agents have reached clinical use in the past two decades than at any other time.
Kathryn Sabol, Tawanda Gumbo
doaj   +5 more sources

Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis [PDF]

Therapeutic Advances in Infectious Disease
Background: Echinocandins are recommended as an initial treatment for invasive candidiasis. Although safety and efficacy profiles of both anidulafungin and caspofungin are well established, direct head-to-head comparisons have not been reported before ...
Reem Hasan Elajez, Dana Bakdach, Sara Al Balushi, Ahmed Zaqout, Rand Alattar, Tasneem Abdallah, Waleed Awouda, Godwin Wilson, Walid Al-Wali, Emad Ibrahim, Hussam Alsoub   +10 more
doaj   +3 more sources

In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against Four Candida auris Clades [PDF]

Pharmaceutics, 2023
Candida auris is a multidrug-resistant pathogen against which echinocandins are the drug of choice. However, information on how the chitin synthase inhibitor nikkomycin Z influences the killing activities of echinocandins against C.
Awid Adnan, Andrew M. Borman, Zoltán Tóth, Lajos Forgács, Renátó Kovács, Dávid Balázsi, Bence Balázs, Gergely Udvarhelyi, Gábor Kardos, László Majoros   +9 more
doaj   +2 more sources

Discovery of Small-Molecule PD-L1 Inhibitors via Virtual Screening and Their Immune-Mediated Anti-Tumor Effects [PDF]

Pharmaceuticals
Background/Objectives: Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have achieved clinical success but face drawbacks such as poor oral bioavailability, limited tumor penetration, and immune-related adverse events.
Chunlai Feng, Yingying Ge, Siqi Wang, Mengru Li, Qiying Chen, Hangyu Dong, Mengjie Rui   +6 more
doaj   +2 more sources

<i>Candida parapsilosis</i> and echinocandins: should the clinical laboratory drop anidulafungin Etest from the susceptibility testing panel? [PDF]

Antimicrob Agents Chemother
Vahedi-Shahandashti R, Moroder E, Lass-Flörl C.   +2 more
europepmc   +2 more sources

Evaluating the Efficacy and Safety of Anidulafungin and Caspofungin in Invasive Candida Infections in Intensive Care Units in India: A Prospective, Observational, Multicenter, Open-Label Study. [PDF]

Cureus
Mehta Y, Rao PV, Mahajan R, Panackel C.
europepmc   +2 more sources

Synthetic Human Lactoferrin Peptide hLF(1-11) Shows Antifungal Activity and Synergism with Fluconazole and Anidulafungin Towards <i>Candida albicans</i> and Various Non-Albicans <i>Candida</i> Species, Including <i>Candidozyma auris</i>. [PDF]

Antibiotics (Basel)
Brouwer C, van der Linden Y, Carrasco MR, Alwasel S, Abalkhail T, Al-Otibi FO, Boekhout T, Welling MM.   +7 more
europepmc   +2 more sources

In Vitro Susceptibilities of Worldwide Isolates of Intrapulmonary Aspergillus Species and Important Candida Species in Sterile Body Sites against Important Antifungals: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2017–2020

Microbiology Spectrum, 2022
To understand the changes of resistance in clinically commonly encountered fungi, we used the Antimicrobial Testing Leadership and Surveillance (ATLAS) database to explore in vitro antifungal susceptibilities against clinically important isolates of ...
Shio-Shin Jean, Hung-Jen Yang, Po-Chuen Hsieh, Yu-Tsung Huang, Wen-Chien Ko, Po-Ren Hsueh   +5 more
doaj   +1 more source

Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. [PDF]

, 2016
Aspergillus spp. are a group of filamentous molds that were first described due to a perceived similarity to an aspergillum, or liturgical device used to sprinkle holy water, when viewed under a microscope.
Stewart, Ethan R, Thompson, George R
core   +8 more sources

Surveillance of Candida spp Bloodstream Infections: Epidemiological Trends and Risk Factors of Death in Two Mexican Tertiary Care Hospitals [PDF]

, 2014
Introduction: Larger populations at risk, broader use of antibiotics and longer hospital stays have impacted on the incidence of Candida sp. bloodstream infections (CBSI).Objective: To determine clinical and epidemiologic characteristics of patients with
Alvarado Matute, Tito, Colombo, Arnaldo L., Cornejo Juárez, Patricia, Cortés, Jorge, Corzo León, Dora E., Echevarría, Juan I., Guzmán Blanco, Manuel, Macías, Alejandro E., Nucci, Marcio, Ostrosky Zeichner, Luis, Ponce de León, Alfredo, Ponce de León, Alfredo, Queiroz Telles, Flavio, Santolaya de Pablo, María Elena, Sifuentes Osornio, José, Thompson Moya, Luis, Tiraboschi, Iris Nora, Zurita, Jeannete   +17 more
core   +14 more sources